Antimutagenic 1,4-Dihydropyridine AV-153 Normalizes Expression of GLUT1, GLUT4, INOS, PARP1, and Gamma H2AX Histone in Myocardium of Rats with Streptozotocin Model of Diabetes Mellitus-Reference-Cited by-同舟云学术

Antimutagenic 1,4-Dihydropyridine AV-153 Normalizes Expression of GLUT1, GLUT4, INOS, PARP1, and Gamma H2AX Histone in Myocardium of Rats with Streptozotocin Model of Diabetes Mellitus

Published:2023-04-01 Issue:2 Volume:77 Page:96-101
ISSN:2255-890X
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
language:en
Short-container-title:

Author:

Rostoka Evita¹,Isajevs Sergejs¹,Sokolovska Jeļizaveta¹,Duburs Gunārs²,Sjakste Nikolajs¹

Affiliation:

1. 1 Faculty of Medicine , University of Latvia , Rīga, 3 Jelgavas Str. LV-1004 , Latvia

2. 2 Latvian Institute of Organic Synthesis , Rīga, LV-1006, 21 Aizkraukles Str ., Latvia

Abstract

Abstract Diabetic cardiomyopathy increases the risk of heart failure and worsens prognosis for diabetes mellitus (DM) patients. Its development depends on many factors, including modification of nitric oxide production and impaired DNA repair. The goal of the present work was to study in vivo effects of a 1,4-dihydropyridine AV-153, known as antimutagen and DNA-binder, on DNA integrity, and on the expression of several proteins involved in glucose transport, nitric oxide metabolism, and DNA repair in myocardium in diabetic rats. DM was induced in rats by streptozotocin (STZ) injection. Expression of proteins was studied by means of immunohistochemistry. Development of the STZ-induced DM significantly induced PARP1 and gamma H2AX histone, markers of DNA breakage, protein expression in heart tissue, while AV-153 administration decreased PARP1 and H2AX protein expression. In this model of diabetes, myocardial expression of iNOS was also significantly increased, but administration of AV-153 reduced it to normal levels. AV-153 also upregulated the expression of insulin-dependent GLUT4 and insulin-independent GLUT1 glucose transporters up to normal level in diabetic rats. Thus, AV-153 appears to be prospective for creation of a remedy for prevention of diabetic cardiomyopathy.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/prolas-2023-0014

Reference33 articles.

1. Bagchi, R. A., Weeks, K. L. (2019). Histone deacetylases in cardiovascular and metabolic diseases. J. Mol. Cell. Cardiol., 130, 151–159.

2. Buraka, E., Chen, C. Y., Gavare, M., Grube, M., Makarenkova, G., Nikolajeva, V., Bisenieks, I., Brūvere, I., Bisenieks, E., Duburs, G., Sjakste, N. (2014). DNA-binding studies of AV-153, an antimutagenic and DNA repair-stimulating derivative of 1,4-dihydropiridine. Chem. Biol. Interact., 220, 200–207.

3. Chanda, D., Luiken, J. J. F. P., Glatz, J. F. C. (2016). Signalling pathways involved in cardiac energy metabolism. FEBS Lett., 590 (15), 2364–2374.

4. Chen, Y., Du, J., Zhao, Y. T., Zhang, L., Lv, G., Zhuang, S., Qin, G., Zhao, T. C. (2015). Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. Cardiovasc. Diabetol., 14, 99.

5. Choi, S. Y., Jeong, H. J., Lim, H. G., Park, S. S., Kim, S. H., Kim, Y. J. (2012). Elimination of alpha-galxenoreactive epitope: alpha-galactosidase treatment of porcine heart valves. J. Heart. Valve Dis., 21, 387–397.